Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions …
Over the last 12 months, insiders at Merck & Co., Inc. have bought $0 and sold $51.62M worth of Merck & Co., Inc. stock.
On average, over the past 5 years, insiders at Merck & Co., Inc. have bought $22,168 and sold $116.07M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3 shares for transaction amount of $341 was made by Romanelli Joseph (President, Human Health Int?l) on 2023‑04‑26.
2024-02-14 | Sale | Chairman, CEO & President | 85,021 0.0034% | $125.40 | $10.66M | -1.80% | ||
2024-02-14 | Sale | EVP & CFO | 38,291 0.0015% | $125.50 | $4.81M | -1.80% | ||
2024-02-13 | Sale | Chairman, CEO & President | 150,000 0.0059% | $125.85 | $18.88M | -1.44% | ||
2024-02-13 | Sale | President, Human Health Int?l | 1,000 <0.0001% | $124.89 | $124,888 | -1.44% | ||
2024-02-09 | Sale | Executive VP & President, MRL | 14,702 0.0006% | $125.50 | $1.85M | -1.36% | ||
2024-02-07 | Sale | EVP,Chief Info&Digital Officer | 1,451 <0.0001% | $127.57 | $185,108 | -2.84% | ||
2024-02-02 | Sale | EVP, General Counsel | 49,499 0.002% | $126.97 | $6.28M | -1.97% | ||
2024-02-02 | Sale | EVP, Chief HR Officer | 50,694 0.0021% | $126.65 | $6.42M | -1.97% | ||
2024-02-02 | Sale | President, U.S. Market | 18,959 0.0008% | $127.17 | $2.41M | -1.97% | ||
2023-11-09 | Sale | President, U.S. Market | 2,081 <0.0001% | $102.38 | $213,061 | +18.05% | ||
2023-11-08 | Sale | EVP&Pres, Merck Animal Heallth | 43,823 0.0017% | $105.03 | $4.6M | +15.54% | ||
2023-08-14 | Sale | EVP, Chief HR Officer | 4,250 0.0002% | $109.01 | $463,293 | +9.17% | ||
2023-08-03 | Sale | EVP, Chief HR Officer | 4,500 0.0002% | $105.49 | $474,701 | +12.35% | ||
2023-08-02 | Sale | President, Human Health Int?l | 89 <0.0001% | $107.37 | $9,556 | +12.37% | ||
2023-05-04 | Sale | Sr. VP Fince-Global Controller | 15,875 0.0006% | $117.53 | $1.87M | -5.86% | ||
2023-05-04 | Sale | EVP, General Counsel | 19,141 0.0008% | $117.59 | $2.25M | -5.86% | ||
2023-05-03 | Sale | EVP, Chief HR Officer | 53,400 0.0021% | $119.01 | $6.36M | -6.47% | ||
2023-05-02 | Sale | EVP,Chief Info&Digital Officer | 7,509 0.0003% | $116.82 | $877,222 | -6.21% | ||
2023-05-01 | Sale | EVP&Pres, Merck Animal Heallth | 75,436 0.003% | $116.03 | $8.75M | -4.96% | ||
2023-04-28 | Sale | Chairman, CEO & President | 143,329 0.0056% | $114.93 | $16.47M | -4.38% |
Romanelli Joseph | President, Human Health Int?l | 19569 0.0008% | $98.05 | 8 | 4 | +0.2% |
HASSAN FRED | Chairman and CEO | 720800 0.0285% | $98.05 | 2 | 0 | <0.0001% |
FRAZIER KENNETH C | Executive Chair | 700653 0.0277% | $98.05 | 1 | 40 | +21.77% |
SABATINO THOMAS J JR | Executive Vice President | 309535 0.0122% | $98.05 | 1 | 0 | |
BERTOLINI ROBERT J | Executive Vice President | 65000 0.0026% | $98.05 | 1 | 0 |
The Vanguard Group | $32.1B | 9.61 | 243.27M | -0.62% | -$198.83M | 0.59 | |
BlackRock | $27.32B | 8.17 | 207.02M | +2.57% | +$683.37M | 0.6 | |
State Street | $15.58B | 4.64 | 117.43M | +0.48% | +$74.26M | 0.64 | |
Wellington Management Company | $11.39B | 3.41 | 86.35M | +0.88% | +$99.26M | 1.93 | |
Geode Capital Management | $7.43B | 2.23 | 56.41M | +1.77% | +$129.4M | 0.63 |